Evaluating Therapeutic Modalities for Prevention and Treatment of Postmenopausal Osteoporosis

Eichner SF , Lloyd KB , Timpe EM . Postmenopausal osteoporosis prevention and treatment: reviewing the evidence of standard therapies. Ann Pharmacother 2003; 37: 711–24.

O'Connell MB . Osteoporosis and osteomalacia. In: DiPiro JT , Talbert RL , Yee GC , Matzke GR , Wells BG , Posey LM , eds. Pharmacotherapy: a physiologic approach. 4th ed. New York: McGraw-Hill, 2002: 1406–25.

Gold DT , Lee LS , Tresolini C P , eds. Working with patients to prevent, treat and manage osteoporosis: a current guide for the health professions. 3rd ed. Durham, NC: Center for the Study of Aging and Human Development, Duke University Medical Center, 2001.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.

U.S. Preventive Service Task Force. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions. AHRQ publication number 03-513A. Rockville, MD. August 2002: 1–9, or visit the AHRQ Web page at www.preventiveservices.ahrq.gov.

Cauley JA , Seeley DG , Ensrud K , Ettinger B , Black DB , Cummings SR . Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9–16.

Hulley S , Furberg C , Barrett-Connor E , Cauley J , Grady D , Haskell W , et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58–66.

White C . Second long term HRT trial stopped early. BMJ 2002; 325: 987.

9 Package insert. Prempro. Philadelphia: Wyeth Pharmaceuticals, December 2002.

10 Package insert. Premarin. Philadelphia: Wyeth Pharmaceuticals, December 2002.

Kusiak V . FDA approves prescribing information for postmenopausal hormone therapies. Philadelphia: Wyeth Pharmaceuticals, January 6, 2003.